Preclinical Pharmacology of OPC-34712: A Novel Compound with Dopamine D2 Receptor Partial Agonist Activity

被引：0
|
作者：
Kikuchi, Tetsuro [1 ]
Maeda, Kenji [1 ]
Sugino, Haruhiko [1 ]
Akazawa, Hitomi [1 ]
Amada, Naoki [1 ]
Jordan, Shaun [2 ]
Shimada, Jun [1 ]
Yamashita, Hiroshi [1 ]
Ito, Nobuaki [1 ]
Forbes, Robert A. [3 ]
McQuade, Robert D. [3 ]
机构：
[1] Otsuka Pharmaceut Co Ltd, Quest Res Inst, Tokushima 77101, Japan
[2] Otsuka Pharmaceut Co Ltd, Otsuka Maryland Med Labs Inc, Rockville, MD USA
[3] Otsuka Pharmaceut Co Ltd, Otsuka Pharmaceut Dev & Commercializat, Princeton, NJ USA
来源：
BIOLOGICAL PSYCHIATRY | 2011年 / 69卷 / 09期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
320
引用
收藏
页码：95S / 95S
页数：1
相关论文
共 50 条
  • [41] Bifeprunox: a novel partial agonist for the D2 receptor with antagonistic capabilities depending on dopaminergic tone
    Hesselink, M
    McCreary, AC
    Glennon, JC
    Herremans, AHJ
    Marquis, K
    Hertel, P
    Arnt, J
    Didriksen, M
    Long, SK
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S486 - S486
  • [42] Novel dopamine D2 partial agonists in the treatment of schizophrenia
    Correll, C.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S668 - S668
  • [43] Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats
    Tarland, Emilia
    Franke, Robert T.
    Fink, Heidrun
    Pertz, Heinz H.
    Brosda, Jan
    [J]. PSYCHOPHARMACOLOGY, 2018, 235 (01) : 99 - 108
  • [44] Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats
    Emilia Tarland
    Robert T. Franke
    Heidrun Fink
    Heinz H. Pertz
    Jan Brosda
    [J]. Psychopharmacology, 2018, 235 : 99 - 108
  • [45] Antipsychotic-like effect and cataleptogenic potential of the dopamine D2 receptor partial agonist 2-bromoterguride
    Brosda, J.
    Franke, R.
    Jantschak, F.
    Pertz, H. H.
    Fink, H.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S13 - S13
  • [46] Favourable behavioural actions of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist antipsychotic candidate
    Gyertyan, I.
    Kiss, B.
    Saghy, K.
    Laszy, J.
    Szabo, G.
    Agai-Csongor, E.
    Domany, G.
    Tihanyi, K.
    Szombathelyi, Z.
    [J]. BEHAVIOURAL PHARMACOLOGY, 2007, 18 : S12 - S13
  • [47] BEHAVIORAL-EFFECTS OF RO-41-9067 - A NOVEL D2 DOPAMINE RECEPTOR AGONIST
    BELZUNG, C
    CARLETTI, P
    ANGELUCCI, F
    PUGLISIALLEGRA, S
    CABIB, S
    [J]. DRUG DEVELOPMENT RESEARCH, 1992, 27 (04) : 425 - 433
  • [48] Characterization of a Novel Dopaminergic Agonist that Displays Spatial Bias and Functional Selectively at the D2 Dopamine Receptor
    Sibley, David
    Free, R. Benjamin
    Shin, J. Hoon
    Miller, Brittney
    Doyle, Trevor
    Moritz, Amy
    Conroy, Jennie
    Brust, Tarsis
    Southall, Noel
    Ferrer, Marc
    Donthamsetti, Prashant
    Javitch, Jonathan
    Watts, Val
    Katz, Jonathan
    Stanwood, Gregg
    Bertz, Jeremiah
    Woods, James
    Emmitte, Kyle
    Lindsley, Craig
    Alvarez, Veronica
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S216 - S217
  • [49] THE PHARMACOLOGY OF CARIPRAZINE, A NOVEL D3-PREFERRING D3/D2 ANTAGONIST-PARTIAL AGONIST ANTIPSYCHOTIC
    Kiss, Bela
    Seneca, Nick
    Szikra, Judit
    Nemethy, Zsolt
    Saghy, Katalin
    Laszy, Judit
    Gyertyan, Istvan
    [J]. SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 379 - 380
  • [50] Bifeprunox mesilate -: Treatment of bipolar disorder treatment of schizophrenia dopamine D2 receptor partial agonist 5-HT1A receptor agonist
    Sorbera, LA
    Castañer, J
    [J]. DRUGS OF THE FUTURE, 2005, 30 (10) : 992 - 997
12345